Cellectar Biosciences (CLRB)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Cellectar Biosciences, with a price target of $7.00. The company’s shares closed last Tuesday at $3.61.
According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -21.2% and a 29.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.